Business · Companies · 22 hrs ago
Avalon Pharma targets 800 million riyals in tirzepatide sales over five years
Avalon Pharma has signed a licensing deal with India-based OneSource Specialty Pharma to register and market tirzepatide in Saudi Arabia and other Middle East and North Africa markets.
Tirzepatide will be sold as a multi-dose pen in strengths from 2.5 to 15 milligrams.
The product is a generic version of Mounjaro QuickPen, a medicine used for diabetes and metabolic diseases.
Avalon expects at least 800 million riyals in total revenue from the product during its first five years after launch.
The product can launch in each market only after the relevant patents expire in that market or in the country where it is made.
The agreement lasts 10 years from commercial launch and then renews automatically one year at a time.
After launch, Avalon can request a transfer of manufacturing technology, which could allow it to make the medicine locally in the future.
Avalon Pharma expects cumulative revenue of at least 800 million riyals from tirzepatide during the first five years after its launch.
The Saudi pharmaceutical company signed an exclusive licensing agreement with India’s One Source Pharmaceuticals.
The agreement covers registration and marketing in Saudi Arabia and other markets in the Middle East and North Africa.
The product is a multi-dose pen in strengths ranging from 2.5 to 15 milligrams and is a generic version of Mounjaro KwikPen.
It may be launched in each market after relevant patents expire, and the agreement lasts 10 years from commercial launch.
- Who
- Avalon Pharma and One Source Pharmaceuticals, an Indian pharmaceutical development, manufacturing and supply company.
- What
- They signed an exclusive licensing agreement for registration and marketing of tirzepatide.
- When
- The agreement was announced on October 11, 2026. The signing date was not stated.
- Where
- Saudi Arabia and other markets in the Middle East and North Africa.
- Why
- Avalon expects at least 800 million riyals in cumulative revenue over five years and aims to strengthen its GLP-1 medicines portfolio and regional presence.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
This story does not have a timeline yet.
- Five-year revenue target
- At least 800 million riyals
- Agreement term
- 10 years from commercial launch, with automatic one-year renewals
- Product strengths
- 2.5 to 15 milligrams
- Covered markets
- Saudi Arabia and other markets in the Middle East and North Africa
- Contract value
- Less than 5% of Avalon Pharma’s total revenue, based on its 2025 annual financial statements
Sources
Related news
Stock and bond futures rise as oil prices retreat
Saudi Arabia says it will keep supplying global energy in all conditions
Investment fund assets reach 1 trillion riyals for the first time
Riyadh Economic Forum to discuss five studies on Saudi priorities
Saudi industrial production fell 23.5% in August
King Salman aid center named among 70 Saudi brands
Riyadh Economic Forum opens with focus on Saudi development priorities
Saudi Energy Minister Calls Riyadh a Center of Energy Security
Saudi energy minister vows commitment after deadly airport attack
Saudi Arabia developing pipelines to bypass the Strait of Hormuz
UAE education company negotiates controlling stake in Saudi school operator
